modernretina.com

Avaliação do site modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Gerado a 31 de Março de 2026 15:12 PM

Estatísticas desatualizadas? ATUALIZE !

O resultado é de 57/100

Conteúdo SEO

Título

Modern Retina – Ophthalmology News, Events & Expert Insights

Cumprimento : 60

Perfeito, o Título contém entre 10 e 70 caracteres.

Descrição

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Cumprimento : 155

Perfeito, a Descrição META contém entre 70 e 160 caracteres.

Palavras-chave

Mau. Não detetámos palavras-chave META na sua página.

Propriedades Og Meta

Boa! Esta página tira vantagens das propriedades Og.

Propriedade Conteúdo
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Cabeçalhos

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Imagens

Encontrámos 135 imagens nesta página.

23 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.

Rácio Texto/HTML

Rácio : 3%

O rácio de texto para código HTML desta página é menor que 15 porcento, o que significa que provavelmente é necessário de adicionar mais conteúdos em forma de texto.

Flash

Perfeito, não foi encontrado conteúdo Flash nesta página.

Iframe

Excelente, não foram detetadas Iframes nesta página.

Reescrita de URL

Perfeito. As ligações aparentam ser limpas!

Underscores (traços inferiores) nas URLs

Perfeito. Não foram encontrados 'underscores' (traços inferiores) nas suas URLs.

Ligações para a própria página

Encontrámos um total de 89 ligações incluindo 0 ligações a ficheiros

Âncoras Tipo Sumo
All News Internas Passa sumo
Blogs Internas Passa sumo
All Videos Internas Passa sumo
Case-Based Roundtable Series Internas Passa sumo
Eichenbaum Acorns Internas Passa sumo
Expert Interviews Internas Passa sumo
Eyeviews Internas Passa sumo
Insights Internas Passa sumo
Medical World News Externas Passa sumo
Podcasts Internas Passa sumo
Rapid Readouts Internas Passa sumo
The Retina TL;DR Internas Passa sumo
Viewpoints Internas Passa sumo
Conference Coverage Internas Passa sumo
Conference Listing Internas Passa sumo
Modern Retina Digital Edition Internas Passa sumo
Supplements And Featured Publications Internas Passa sumo
Between the Lines Internas Passa sumo
CME/CE Internas Passa sumo
EYLEA 8mg for nAMD and DME Treatment Internas Passa sumo
Sponsored Resources Internas Passa sumo
Partners Internas Passa sumo
Subscribe Internas Passa sumo
AMD Internas Passa sumo
Wet AMD Internas Passa sumo
Biosimilar Internas Passa sumo
Diabetic Macular Edema Internas Passa sumo
Diabetic Eye Awareness Internas Passa sumo
Diabetic Retinopathy Internas Passa sumo
Geographic Atrophy Internas Passa sumo
Imaging Internas Passa sumo
Inherited Retinal Diseases Internas Passa sumo
Ophthalmology Internas Passa sumo
RVO Internas Passa sumo
Retina Technology Internas Passa sumo
Retinal Surgery Internas Passa sumo
Uveitis Internas Passa sumo
Geographic Atrophy Internas Passa sumo
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Internas Passa sumo
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Internas Passa sumo
Treating MacTel: First identify patient candidates and appropriate eye selection Internas Passa sumo
A medical fellow finds some magic at the AAO Annual Meeting Internas Passa sumo
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Internas Passa sumo
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Internas Passa sumo
FLORetina 2025: Long-term follow-up in pediatric gene therapy Internas Passa sumo
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Internas Passa sumo
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Internas Passa sumo
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Internas Passa sumo
Martin David Harp Internas Passa sumo
Christina Y. Weng, MD, MBA, FASRS Internas Passa sumo
View All Internas Passa sumo
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Internas Passa sumo
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Internas Passa sumo
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Internas Passa sumo
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Internas Passa sumo
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Internas Passa sumo
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Internas Passa sumo
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Internas Passa sumo
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Internas Passa sumo
Integrating AI to manage DR in a primary care setting Internas Passa sumo
What to expect from virtual AAO 2020 Internas Passa sumo
View More Internas Passa sumo
Navigating geographic atrophy from biomarkers to bilateral therapy Internas Passa sumo
8 things to know about aflibercept 8 mg for retinal vascular disease Internas Passa sumo
Inside the mindset of an early adopter Internas Passa sumo
Challenges for young physicians treating patients with GA Internas Passa sumo
AAO highlight: Looking ahead to 2026 Internas Passa sumo
How AI is reshaping ophthalmology in 2025 and beyond Internas Passa sumo
Seeing the difference: Multimodal imaging for AMD and GA Internas Passa sumo
Ryan Livingston Internas Passa sumo
Lynda Charters Internas Passa sumo
Kevin Kunzmann Internas Passa sumo
Jeffry D. Gerson, OD, FAAO Internas Passa sumo
Theodore Leng, MD, MS Internas Passa sumo
Sheryl Stevenson Internas Passa sumo
Joshua Mali, MD Internas Passa sumo
Arshad M. Khanani, MD, MA, FASRS Internas Passa sumo
Modern Retina Staff Reports Internas Passa sumo
Jayanth Sridhar, MD Internas Passa sumo
Matt Hoffman Internas Passa sumo
Sheila Setork, OD Internas Passa sumo
About Internas Passa sumo
Advertise Internas Passa sumo
Editorial Internas Passa sumo
Contact Us Internas Passa sumo
Terms and Conditions Internas Passa sumo
Privacy Internas Passa sumo
Do Not Sell My Personal Information Externas Passa sumo
Home Internas Passa sumo

Palavras-chave SEO

Núvem de palavras-chave

more fasrs cope cme video retinal faao view management track

Consistência das Palavras-chave

Palavra-chave Conteúdo Título Palavras-chave Descrição Cabeçalhos
more 64
view 52
video 44
track 35
faao 24

Usabilidade

Url

Domínio : modernretina.com

Cumprimento : 16

Favicon

Ótimo, o site tem um favicon.

Facilidade de Impressão

Não encontrámos CSS apropriado para impressão.

Língua

Otimo! A língua declarada deste site é en.

Dublin Core

Esta página não tira vantagens do Dublin Core.

Documento

Tipo de Documento

HTML 5

Codificação

Perfeito. O conjunto de caracteres UTF-8 está declarado.

Validação W3C

Erros : 0

Avisos : 0

Privacidade do Email

Aviso! No mínimo, foi encontrado um endereço de email sob a forma de texto. Isto é um convite para que spammers entupam a caixa de correio deste endereço.

HTML obsoleto

Fantástico! Não detetámos etiquetas HTML obsoletas.

Dicas de Velocidade

Excelente, este site não usa tablelas dentro de tabelas.
Oh não, o site usa estilos CSS nas etiquetas HTML.
Boa, o site usa poucos ficheiros CSS.
Oh, não! O site utiliza demasiados ficheiros JavaScript (mais que 6).
Perfeito, o site tira vantagens da compressão gzip.

Dispositivos Móveis

Otimização para dispositivos móveis

Icon Apple
Meta Viewport Tag
Conteúdo Flash

Otimização

XML Sitemap

Perfeito, o site tem um mapa XML do site (sitemap).

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Perfeito, o seu site tem um ficheiro robots.txt.

Analytics

Perfeito, o site tem uma ferramenta analítica para a análise de atividade.

   Google Analytics

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site